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Abstract 
Background: An efficient strategy for programing dendritic cells (DCs) for cancer immunotherapy is the optimiza‑
tion of their maturation so that they can efficiently stimulate cancer‑specific T cell responses. Interleukin (IL)‑4 has 
appeared as an essential cytokine, widely used in vitro with granulocyte macrophage‑colony stimulating factor 
(GM‑CSF) to differentiate monocytes into immature DCs (iDC) and to prevent macrophage formation. Conflicting data 
have been published regarding the effect of IL‑4 on functional DC maturation. To further understand IL‑4’s effects on 
DC maturation and function in vitro, we choose the most commonly used maturation factor tumor necrosis factor 
(TNF)‑α.
Methods: Human monocyte‑derived iDC were treated for 48 h with GM‑CSF and TNF‑α in the presence (IL‑4+‑DC) or 
absence (IL‑4−‑DC) of IL‑4 and functions of both DC populations were compared.
Results: On mixed lymphocyte reaction assay, IL‑4+‑DC were less potent than IL‑4−‑DC at inducing the proliferation 
of allogeneic CD4+ T cells and the proportion of activated T cells expressing CD69 and/or CD25 was smaller. Interleu‑
kin‑4 reduced the cell‑surface expression of TNF‑α‑induced DC maturation markers CD83, CD86, HLA‑DR and CD25 
and generated a heterogeneous population of DCs. IL‑4+‑DC secreted less IL‑12 and more IL‑10 than IL‑4−‑DC follow‑
ing activation by soluble CD40L, and IL‑4+‑DC‑activated T cells secreted lesser amounts of T helper (Th) 1 cytokines 
(IL‑2 and interferon‑γ). Importantly, IL‑4 impaired the in vitro migratory capacity of DCs in response to CCL21 and 
CCL19 chemokines. This effect was related to reduced expression of CCR7 at both mRNA and protein levels.
Conclusion: Interleukin‑4 used with GM‑CSF and TNF‑α during the maturation of DCs in vitro impaired DC functions 
and disturbed the maturation effect of TNF‑α. Finally, our study reinforces the view that the quality of the DC matura‑
tion stimulus, which regulates DC migration and cytokine production, may be a decisive feature of the immunogenic‑
ity of DCs.
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Background
Dendritic cells (DCs) are the most potent antigen-pre-
senting cells (APC) and play a pivotal role in the ini-
tiation of the primary immune response [1]. They are 
generated in  vitro in large quantities from peripheral 
blood monocytes and are commonly used in active 
cancer immunotherapy. Results obtained over the last 
15 years have highlighted the poor clinical efficacy of DC-
based vaccine, related essentially to an ineffective migra-
tion of injected DCs to the peripheral lymphoid organs 
and insufficient T-cell help secondary to inadequate anti-
gen presentation by major histocompatibility complex 
(MHC) class II [2]. Today, a large number of several strat-
egies have developed; some using DC targeting combined 
with chemotherapy or agonists of TLRs, others interested 
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by DC subsets [3]. Whatever these strategies, monocyte-
derived DCs appeared always as one relevant actor in 
cancer immunotherapy [4].
The manner by which DCs are matured in  vitro is 
clearly an important variable that governs their subse-
quent functionality. Upon maturation, DCs up-regulate 
the expression of molecules such as CD80 and CD86 for 
co-stimulation, as well as MHC, and produce cytokines 
that are instructive signals mirroring the micro-environ-
ment in which they were activated [5]. These different 
stimuli contribute to differential levels of T cell activation 
and T helper (Th) polarization of the immune response 
[6]. For the design of DC-based vaccines for immu-
notherapy against tumors, the challenge is to find the 
most potent source of DCs and the appropriate cytokine 
milieu for maturation to induce Th1-cell differentiation 
[7, 8]. The most widely used protocols for maturation of 
clinical grade monocyte-derived DC include the use of 
granulocyte macrophage-colony stimulating factor (GM-
CSF) and interleukin (IL)-4 in combination with tumor 
necrosis factor (TNF)-α alone or with IL-1β, IL-6 and 
prostaglandin (PG) E2, also known as “the maturation 
cocktail” [9, 10]. This cocktail was challenge because of 
low production of IL-12p70 and the induction of Th2-
type immune responses. TNF-α used alone is a well-
known factor able to induce high expression levels of 
MHC class II and co-stimulatory molecules on DCs but 
is known as a weak stimulator of IL-12 production, CCR7 
expression and DC migration [11]. However at least in 
mice, dendritic cells matured with TNF-α can be further 
activated in vitro and after subcutaneous injection in vivo 
a process that converts their tolerogenicity into immuno-
genicity [12].
In many cell types, it is well known that IL-4 has anti-
TNF-α and anti-inflammatory effects [13]. Interleukin-4 
is necessary for the differentiation of monocytes into 
immature DCs (iDC) in vitro. It has been demonstrated 
that monocytes cultivated with GM-CSF and TNF-α 
alone from the beginning of the culture, were converted 
to CD14 positive/CD1a low-adherent cells with a lower 
capacity to stimulate T cells [14]. Moreover, the use of 
IL-4 with GM-CSF during the differentiation step of 
monocytes into iDC has been shown to overcome the 
problem of donor diversity, which results from the varia-
bility in GM-CSF receptor alpha expression, and allowed 
a more homogeneous population of iDC to be generated 
[15].
Conflicting data have been published regarding the 
effect of IL-4 on functional DC maturation. IL-12p70 
production by DCs is increased by IL-4 in lipopolysac-
charide (LPS)- and CD40L-matured DC [16]. Other stud-
ies have reported that the use of IL-4 to generate DC for 
therapeutic use could be inappropriate if the objective is 
to induce long-term Th1 responses [17]. Furthermore, a 
few studies have suggested that continuous, high concen-
trations of IL-4 during DC maturation with LPS [18] or 
polyinosinic:polycytidylic acid (poly I:C) [19], may gen-
erate disabled DCs through suppression of the mobiliza-
tion of endogenous PGE2. Moreover, migration capacity 
of DCs could also be impaired in the presence of IL-4 as 
observed on human Langerhans cells by down regulation 
of TNF-R II [20].
To further understand IL-4’s effects on DC matura-
tion and function in  vitro, we choose the most com-
monly used maturation factor tumor necrosis factor 
(TNF-α) and we hypothesized that the combined use of 
IL-4 and TNF-α during the maturation step of DC might 
be responsible for their phenotypic and functional defi-
ciency. A better understanding of the role of cytokines 
in the differentiation and maturation of DC could lead to 
promising new developments in the design of more effec-
tive and rational DC-vaccine strategies.
Methods
Generation of IL‑4− and IL‑4+ DC
Human iDC were generated in  vitro as previously 
described [21]. Peripheral blood mononuclear cells 
(PBMC) were obtained via cytapheresis, from the 
blood of healthy volunteers who had given their written 
informed consent and the University ethic committee 
approved the procedure. Adherent monocytes were cul-
tured in RPMI-1640 medium supplemented with 10  % 
(v/v) heat-inactivated fetal calf serum (FCS), 2 mM l-glu-
tamine, 50  U/ml penicillin and 50  µg/mL streptomycin 
(Invitrogen, Cergy-Pontoise, France) supplemented with 
1000  U/mL recombinant human (rh) GM-CSF (AbCys 
S.A., Paris, France) and 25 ng/mL rh IL-4 (R&D Systems 
Europe, Abingdon, UK) for 5  days. Fresh medium con-
taining rhGM-CSF and rhIL-4 was added on Day 3 (0.5 
volume). Immature DC were extensively washed with 
RPMI and then stimulated by the addition of 20 ng/mL 
TNF-α (R&D Systems Europe) for 48  h, in the absence 
(IL-4−-DC) or presence (IL-4+-DC) of 25  ng/mL IL-4. 
For the IL-4 and IL-13 dose-dependent experiments, 
iDC were activated with GM-CSF, TNF-α and 0, 0.5, 1, 
5 or 25 ng/mL IL-4 or IL-13 (R&D Systems Europe) for 
48  h. For time-dependent experiments they were acti-
vated for 0, 8, 24 or 48  h in the absence or presence of 
25  ng/mL IL-4. For the IL-4 effect on TNF-α, LPS or 
sCD40L-induced CCR7 cell-surface expression, iDC 
were treated with GM-CSF and 20 ng/mL TNF-α, 50 ng/
mL LPS (Sigma-Aldrich, Saint Quentin Fallavier, France) 
or 250  ng/ml sCD40L pre-incubated with its enhancer 
(Alexis Biochemicals, San Diego, CA, USA) in the pres-
ence or absence of 25  ng/mL IL-4. The cells were then 
harvested. Viability, measured by a Trypan blue exclusion 
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test, was found to be greater than 95 %. The purity of the 
DC preparations, determined by flow cytometry analysis 
of CD1a and DC-SIGN expression on total cultured cells, 
was also greater than 95 %.
FACS analysis
Interleukin-4− and IL-4+ DC, obtained after 7-day cul-
ture, were labeled with monoclonal antibodies (mAbs) 
for human DC-SIGN (clone AZND1), CD1a (clone 
HI149), CD83 (clone HB15a), CD86 (clone HA5.2B7), 
HLA-DR (clone B8.12.2; all from Beckman Coulter, 
Roissy, France), CD25 (clone M-A251; BD Biosciences, 
Le pont de Claix, France), CCR7 (clone 150503; R&D 
Systems Europe), conjugated with fluorescein isothio-
cyanate (FITC), phycoerythrin (PE) or allophycocyanin 
(APC). Cells were also stained with the corresponding 
FITC-, PE- or APC-conjugated isotype-matched control 
mAbs.
For CCR7 intracellular staining (rat PE-anti-CCR7 
mAb, clone 3D12; BD Biosciences), cells were pre-incu-
bated for 30 min at 37 °C with purified anti-CCR7 mAb 
(clone 150503) to neutralize cell-surface expression of 
CCR7. The cells were then fixed and permeabilized using 
IntraPrep Permeabilization Reagent (Beckman Coulter) 
according to the manufacturer’s instructions.
Human CD4+ T cells, co-cultured with IL-4− or IL-
4+-DC for 5  days, were stained with FITC-anti-CD3 
(clone UCHT1), PE-anti-CD69 (clone TP1.55.3; both 
from Beckman Coulter) and APC-anti-CD25 mAbs. 
Intracellular staining with APC-anti-interferon (IFN)-γ 
(clone B27; BD Biosciences) mAb was performed at days 
5 and 6 of the co-culture, after a 4-h incubation of the 
cells with Golgi Stop (BD Biosciences) and IntraPrep Per-
meabilization Reagent (see above). At least 5000–10,000 
cells were obtained, measured using a 488-nm laser flow 
cytometer (FACSCalibur, BD Biosciences). Data were 
analyzed using CELLQuest® software (BD Biosciences). 
The results are expressed as the percentage of labeled 
cells or as the ratio of mean fluorescence intensity (MFI) 
of specific labeling to background staining.
Allogeneic mixed lymphocyte reaction (MLR)
Allogeneic human CD4+ T cells were purified using a 
CD4-positive isolation kit (Dynal France SA, Compiègne, 
France) as described [22]. CD4+ T cells (1  ×  105/well) 
were co-cultured in triplicate with an increasing num-
ber (1 × 104, 3 × 104, 1 × 105/well) of IL-4− or IL-4+ DC 
in 96-well plates, over a five-day period. Dendritic cells 
alone (1 × 105/well) were used as a control. T-cell prolif-
eration was evaluated by the addition of 0.5 µCi/well of 
3H thymidine (Amersham, France) 18 h before the end of 
the co-culture. Radioactivity was quantified on a β coun-
ter (Tri-Carb 2550, Packard, Rungis, France).
Cytokine detection by enzyme‑linked immunosorbent 
assay (ELISA)
For the determination of IL-12p70 and IL-10 release, 
IL-4− and IL-4+-DC were stimulated for 24  h with 
250  ng/mL recombinant sCD40L (Alexis Biochemicals). 
Supernatants were collected and stored at −80  °C. The 
IL-12p70 and IL-10 concentrations were determined by 
ELISA (eBioscience, San Diego CA, USA), according to 
the manufacturer’s instructions. The cytokines in the 
supernatants were measured in the MLR assay using a 
specific ELISA for IL-2, IFN-γ, and IL-5 (eBioscience), 
according to the manufacturer’s instructions.
RT‑Rt‑PCR
The total mRNA was isolated from 5 × 105 IL-4− or IL-4+ 
DC by use of the Dynabeads mRNA Direct kit (Dynal 
France SA), according to the manufacturer’s instructions. 
This total mRNA was then reverse-transcribed for 1 h at 
45  °C in 1X incubation buffer containing 250 µM deox-
ynucleotide triphosphate, 5  µM oligo (dT)20, 12 units 
of RNase inhibitor and 10 units of AMV Reverse Tran-
scriptase (Invitrogen, France).
Standard PCR was then performed with cDNA 
obtained from 5  ×  104 cells in a total reaction volume 
of 50  µL, containing 10  mM Tris–Hcl, pH 9.0, 50  mM 
KCl, 0.01  % (w/v) gelatin, 1.5  mM MgCl2, 0.1  % Triton 
X-100, 50  µM deoxynucleoside triphosphate, 1  µM of 
forward- and reverse-synthesized oligonucleotide prim-
ers (Invitrogen), and 1 unit Super Taq® DNA polymer-
ase (A.T.G.C. Biotechnologie, Noisy-le-Grand, France). 
The primers used for the PCR of CCR7 and for β-actin 
(Sigma-Proligo), acting as a control, were as follows: for-
ward, 5′-TCCTTCTCATCAGCAAGCTGTC-3′, and 
reverse, 5′-CTTCAAGGACCTGGGCTGCCTC-3′; 
and forward, 5′-AGCGGGAAATCGTGCGTG-3′, and 
reverse, 5′-GGCACCACCATGTACCCTG-3′, respec-
tively. The amplification reaction included denaturation 
at 94 °C for 5 min followed by 30 cycles at 94 °C for 30 s, 
53 °C for 30 s and 72 °C for 1 min, and a final extension 
step at 72  °C for 7  min. The MyCycler Thermal Cycler 
system (Biorad, Marnes la Coquette, France) was used 
for this reaction. The amplified fragments were size-sep-
arated on 1.6  % agarose gel and visualized by ethidium 
bromide staining. The band intensities of PCR products 
were measured by use of Image J software (US National 
Institutes of Health).
Chemotaxis assay
The chemotaxis of IL-4− and IL-4+ DC to rhCCL21 
and rhCCL19 (R&D Systems) was assayed in 24-well 
cell culture plates with bare 8.0-µm-pore polycarbon-
ate cell-culture inserts (Corning BV, Schiphol-Rijk, The 
Netherlands). Dendritic cells were washed extensively in 
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RPMI-1640 medium to remove FCS and re-suspended 
in RPMI-1640 containing 1  % (v/v) human serum albu-
min (HSA, LFB, France) at a concentration of 5  ×  105 
cells/100  µL. For optimal induction of DC migration, 
600  µL of RPMI 1640-1  % (v/v) HSA alone, or with 
rhCCL21 or rhCCL19 at 500 or 1000 ng/mL, was added 
to the wells. Each condition was set up in duplicate. 
A100 µL cell suspension (5 × 105 DC) in RPMI-1 % HSA 
was then added to the inserts and the plates were incu-
bated for 5 h at 37  °C, in 5 % CO2. The cells remaining 
in the inserts were subsequently removed; aspiration and 
wiping with cotton harvested swabs, and migrated cells 
by washing the base of the filter insert and the wells with 
600  µL RPMI-1640. Migrated cells were counted using 
a Malassez chamber. The number of cells that spon-
taneously migrated towards the medium alone (with-
out chemokines) was deduced from specific migration 
toward medium with chemokines. Results are expressed 
as the mean number of migrating cells ± SEM.
Statistical analysis
The Mann–Whitney or Wilcoxon signed-rank test 
assessed the significance of differences between means 
using Statview software (SAS Institute, Berkeley, CA). A 
P < 0.05 was considered statistically significant.
Results
IL‑4+‑DC show reduced capacity for stimulation 
of allogeneic CD4+ T‑cells
To evaluate the effect of IL-4 on DC function, we used 
IL-4−- or IL-4+-DC as stimulating cells in co-culture 
with allogeneic CD4+ T cells for MLR assay. Co-culture 
of IL-4−-DC with CD4+ T cells induced allogeneic T-cell 
proliferation that strongly increased with DC number 
(max 1:1 DC/T-cell ratio). Conversely, this response was 
impaired when high concentrations of IL-4+-DC were 
used (Fig.  1a). Dendritic cells cultured alone did not 
proliferate, which verified that the assay detected only 
the allogeneic T-cell responses (Fig. 1a). On flow cytom-
etry analysis, IL-4+-DC induced a lower percentage of 
activated CD4+ T cells expressing CD69 and/or CD25 
than did IL-4−-DC (40 versus 60 %; Fig. 1b, c). Analysis 
of each CD4+ T-cell sub-population showed a strong 
effect of IL-4+-DC on CD69 expression, causing it to be 
reduced almost by half (Fig. 1b, c).
IL‑4 decreases the Th1 cell‑inducing potential 
of TNF‑α‑matured DCs
The orientation of the immune response induced by 
IL-4− or IL-4+-DC was evaluated by the production of 
lymphocytes Th1 (IFN-γ, and IL-2), Th2 (IL-5) and Treg 
(IL-10)-associated cytokines into the co-culture superna-
tants from allogeneic MLR. Interleukin-4−-DC induced 
a strong secretion of IFN-γ and IL-2 in the co-culture 
supernatants that was reduced by two- or three-fold when 
IL-4+-DC were used (Fig. 1d). The secretion of IL-5 was 
weakly detected in both IL-4 conditions, values being 
less than 30  pg/mL, and was significantly weaker on IL-
4+-DC/CD4+ co-culture (Fig.  1d). Since IFN-γ may be 
secreted by DCs themselves, intracellular staining for this 
cytokine was performed on CD4+ T cells and analyzed by 
flow cytometry (labeled cells were gated on CD3+/DC-
SIGN− cells). Interleukin-4−-DC induced approximately 
50  % of T cells positive for intracellular IFN-γ (Fig.  1e). 
The percentage of IFN-γ-positive CD4+ T cells and MFI 
were both reduced by half when IL-4+-DC were used in 
the co-culture (Fig.  1e, f ). This effect was significant at 
days 5 and 6 of the co-culture (P < 0.05; Fig. 1f ). However, 
less than 1 % of CD4+ T cells positive for intracellular IL-4 
were detected by flow cytometry, even after stimulation 
with PMA and ionomycin at the end of the co-culture 
with both types of IL-4-DC (data not shown). Interleu-
kin-10 was weakly detected in both conditions, with no 
significant difference in secretion (data not shown).
IL‑4 reduces the expression of maturation markers 
and IL‑12 secretion of TNF‑α‑treated DCs
To understand the decreased capacity of DC with regard 
to allogeneic T cell stimulation, the cells were cul-
tured for 48 h with GM-CSF and TNF-α in the absence 
(See figure on next page.) 
Fig. 1 IL‑4+‑DC have reduced capacity to induce proliferation and activation of allogeneic CD4+ T cells. a In the MLR assay, allogeneic CD4+ T 
cells (1 × 105/100 µL) were co‑cultured with increasing numbers of IL‑4− or IL‑4+‑DC (1 × 104, 3 × 104 or 1 × 105/10 µL) for 5 days. Dendritic cells 
alone (1 × 105/100 µL) were used as a control. Proliferation was measured by the addition of 3H thymidine 18 h before the end of the co‑culture 
and radioactivity was quantified on a β counter. The results are representative of three independent experiments. b Allogeneic CD4+ T cells 
(1 × 105/100 µL), co‑cultured with IL‑4− or IL‑4+‑DC (3 × 104/100 µL) for 5 days, were removed, stained with specific mAb for CD69 and CD25, 
or their isotype controls, and analyzed by flow cytometry. Labeled cells were gated on CD3+/DC‑SIGN− cells. c The results are expressed as the 
mean ± SEM  % of CD4+ T cells expressing the indicated markers of six independent experiments. *P < 0.05, compared to IL‑4−‑DC/CD4+. d IL‑4− 
and IL‑4+‑DC (3 × 104/100 µL) were co‑cultured with allogeneic CD4+ T cells (1 × 105/100 µL) for 5 days and the supernatants were analyzed for 
IL‑2, IFN‑γ, and IL‑5, using ELISA. The results are the mean ± SEM of six to eight separate experiments. *P < 0.05, compared to IL‑4−‑DC/CD4+. e 
Flow cytometry analysis of intracellular IFN‑γ content. CD4+ T cells were fixed, permeabilized and stained with APC‑anti‑IFN‑γ mAb (bold lines) or its 
isotype control (thin lines). The histograms are representative of five experiments. f MFI of IFN‑γ labeling calculated from the total fraction of CD4+ 
T cells at days 5 and 6 of co‑culture. The results are the mean ± SEM of the MFI of labeled cells from four to five separate experiments. *P < 0.05, 
compared to IL‑4−‑DC/CD4+
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or presence of IL-4. Flow cytometry analysis revealed 
that 100  % of DC populations were CD11c +  (data not 
shown). IL-4−-DC expressed the maturation markers 
CD83, CD86 and HLA-DR, with almost 100  % of cells 
being positive (Fig. 2a). A lower percentage of IL-4+ than 
IL-4− DC were positive for CD83, CD86, HLA-DR and 
CD25 (Fig.  2a), and the MFI for all these markers was 
also lower (P < 0.05; Fig. 2b). The latter effect was dose-
dependent (data not shown) and varied depending on the 
donor.
The majority of cells were CD83+/CD25+ in IL-4− 
DC as shown by analyses of the double staining CD83/
CD25 population (Fig. 2c). Treatment with IL-4 induced 
a significant decrease in CD83+/CD25+ DC whereas it 
increased CD83+/CD25− DC (P < 0.005, Fig. 2d).
Since the secretion of IL-12p70 could not be detected 
after treatment with TNF-α alone (data not shown), 
Interleukin-4− and IL-4+-DC were stimulated for 24  h 
with recombinant sCD40L, thus mimicking a T cell 
encounter. ELISA revealed that IL-4+-DC secreted less 
IL-12p70 and more IL-10 than did IL-4−-DC (P < 0.05) 
(Fig.  2e). Taking these results together, Interleukin-4 
appeared to have an inhibitory effect on the maturation 
marker expression and Th1 orientation profile capacity of 
DC.
IL‑4 decreases TNF‑α matured DC migration toward CCL21 
and CCL19
As migratory capacity is an important competence of 
DCs in immunotherapy, we investigated the effect of IL-4 
on the chemotactic migration of DCs toward the CCR7 
ligands CCL21 and CCL19. In the absence of chemokines 
(medium alone), IL-4+-DC showed an unspecific migra-
tion greater than that of IL-4−-DC (data not shown). 
Interleukin-4−-DC exhibited a strong chemotactic 
response to both CCL21 and CCL19, which was optimal 
at a concentration of 1000 ng/mL (Fig. 3a, b). Treatment 
with IL-4 significantly reduced the migration of DC to 
both chemokines, the effect being maximal at 1000  ng/
mL, with up to 45 % inhibition of CCL19-induced chem-
otaxis (Fig. 3b).
IL‑4 decreases the CCR7 up‑regulation in TNF‑α‑maturated 
DC
CCR7 is a crucial receptor involved in DC function 
in  vivo because it governs cell migration to the drain-
ing lymph nodes. Flow cytometry analysis revealed that 
IL-4−-DC were strongly positive for CCR7 cell-surface 
expression (Fig. 3c, d). The addition of IL-4 inhibited the 
TNF-α-induced up-regulation of CCR7 expression by 
two- or threefold (Fig. 3d). RT-PCR analysis revealed that 
iDC synthesized very low levels of CCR7 mRNA, how-
ever the expression was strongly increased in IL-4−-DC 
after 48-hour treatment with TNF-α and GM-CSF 
(Fig. 4a, b). In the presence of IL-4, TNF-α-induced up-
regulation of CCR7 mRNA synthesis was impaired, 
which resulted in lower CCR7 intracellular protein con-
tent in IL-4+_ than in IL-4−-DC (P  <  0.05; Fig.  4c, d). 
Time dependent experiments with 25  ng/mL of IL-4 
revealed an inhibitory effect after only 8 h of treatment, 
which subsequently increased along the incubation 
time (Fig.  4e). This effect was dose-dependent and was 
observed not only with an IL-4 dose of 25 ng/mL but also 
with as little as 1  ng/mL (Fig.  4f ). Replacing IL-4 with 
IL-13 had the same dose-dependent inhibitory effect on 
CCR7 cell-surface expression (Fig.  4f ). To investigate 
whether the inhibitory effect of IL-4 on CCR7 expression 
was limited to TNF-α-treated DCs, other stimuli were 
included in this study. Treatment with LPS or sCD40L 
for 48 h did not significantly reduce the IL-4 inhibition of 
CCR7 expression (Fig. 4g).
IL‑4 induces an immature profile of DCs associated 
with lower CCR7 expression
To evaluate precisely which DC population was express-
ing a lower amount of CCR7, staining for CD83, CD25 
and CCR7 was performed on IL-4− and IL-4+-DC. 
Double staining of IL-4−- and IL-4+-DC for CD83 and 
CCR7 revealed that all CCR7+ cells were CD83+ in the 
five tested donors, since no CD83−/CCR7+ cells were 
detected (Fig.  5a, b). Interleukin-4 treatment decreased 
the percentage of CD83+/CCR7+ cells and increased the 
percentage of CD83+/CCR7− cells (P  <  0.05; Fig.  5b). 
(See figure on previous page.) 
Fig. 2 IL‑4 impairs TNF‑α‑induced cell‑surface expression of DC maturation markers. Dendritic cells were derived from human monocytes cultured 
for 5 days with GM‑CSF (1000 IU/mL) and IL‑4 (25 ng/mL). Maturation was induced after an additional 48‑h culture with GM‑CSF and 20 ng/mL TNF‑
α, in the absence (IL‑4−) or presence (IL‑4+) of 25 ng/mL IL‑4. a Cells were stained with specific mAbs directed against CD83, CD86, HLA‑DR or CD25 
(bold lines) or their respective isotype controls (thin lines) and analyzed by flow cytometry. The figure in each histogram indicates the percentage of 
positive cells. The results are representative of 10 independent experiments. b Mean fluorescence intensity (MFI) for CD83, CD86, HLA‑DR and CD25 
expressed as the ratio of fluorescence intensity of specific labeling to background staining. The results are the mean ± SEM of MFI of ten separate 
experiments. *P < 0.05, compared to IL‑4−‑DC. c Cells were double‑stained with FITC‑anti‑CD83 and APC‑anti‑CD25 antibodies and analyzed by 
flow cytometry. d The results are expressed as the mean ± SEM  % of IL‑4− and IL‑4+‑DC expressing the indicated markers in five separate experi‑
ments. *P < 0.05, compared to IL‑4−‑DC. e IL‑4− and IL‑4+‑DC were stimulated during an additional 24‑h culture with 250 ng/mL recombinant solu‑
ble CD40L and underwent ELISA for IL‑12p70 and IL‑10 release. The results are the mean ± SEM of six to eight independent experiments. *P < 0.05, 
compared to IL‑4−‑DC
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Thus, the extent of CCR7 inhibition strongly exceeded 
that of CD83 inhibition. Double staining for CCR7 
and CD25 revealed that almost 50  % of IL-4−-DC were 
CCR7+/CD25+ (Fig. 5c, d). Treatment with IL-4 strongly 
decreased this cell population and significantly enhanced 
the percentage of CCR7−/CD25− cells (P < 0.05; Fig. 5d). 
Overall, IL-4 is in favor of a CD83+/CD25−/CCR7− DC 
profile.
Discussion
Ex vivo-generated DCs have been used as therapeutic 
vaccines in patients with cancer for over a decade [6]. 
Increasing knowledge on DC subsets and maturation is 
leading to a better definition of the essential parameters 
for DC therapy success. Our study revealed that IL-4 
antagonized the stimulatory effect of TNF-α on DC’s 
migratory and immuno-stimulatory functions in  vitro, 
an effect that might impair the potential efficacy of DCs 
used as vaccines for cancer immunotherapy in vivo.
Since the first cocktail of cytokines reported by Jonuleit 
in 1997 [10], numerous methods of inducing DC matura-
tion have been developed [8, 23]. To date, CD40L, TNF-α 
and a cocktail of cytokines have been applied in clinical 
trials [24]. TNF-α, one of the important pro-inflamma-
tory cytokines usually present in the maturation cock-
tail has an effect on phenotypic and functional changes 
in DC mediated via TNF-RI [9]. The binding of TNF-α 
to TNF-RI initiates complex signaling events, includ-
ing protein tyrosine kinase-dependent cascades leading 
to the activation of NF-κB and AP-1 that regulate the 
expression of numerous immune/inflammatory response 
genes including IL-12 p70 and CCR7 [25–28].
Induction of an effective immune response depends on 
the proper functional maturation of DCs [5, 6]. In can-
cer, DCs inducing a Th1 response consequently favor an 
efficient cytotoxic immune response. In our study, the 
reduced capacity of IL-4+-DC to stimulate the prolifer-
ation and activation of allogeneic CD4+ T cells may be 
Fig. 3 IL‑4 impairs the migration of TNF‑α‑matured DC towards CCL21, CCL19 and CCR7 expression. a, b The chemotactic migration of IL‑4− and 
IL‑4+‑DC in response to rhCCL21 and rhCCL19 (500 or 1000 ng/mL) was assayed in vitro. Serum‑free medium, either alone or with CCL21 or CCL19, 
was added to the wells, followed by 5 × 105 DC. For each experiment, non‑specific migration in medium alone was deducted from specific migra‑
tion in response to each chemokine. The data represent the mean ± SEM of migrated DC from five separate experiments. *P < 0.05, compared to 
IL‑4−‑DC. c IL‑4− and IL‑4+‑DC were stained with PE‑anti‑CCR7 antibody (bold lines) or its isotype control (thin lines) and analyzed by flow cytometry. 
The results are representative of 11 independent experiments. d Mean fluorescence intensity (MFI) of surface CCR7 content expressed as the ratio of 
fluorescence intensity of specific labeling to background staining. The results are the mean ± SEM of the MFI of six independent experiments
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due in part to the low expression of co-stimulatory and 
MHC II molecules on the surface of these DCs and to a 
reduced secretion of IL-2. IL4+-DC activated allogeneic 
T cells in an incomplete manner with lower percentage 
of CD69+ and/or CD25+ T cells, which could explain the 
reduced proliferating response. Moreover, IL-4 strongly 
impaired the expression of CD25 (IL-2-Rα subunit) 
induced by TNF-α on the surface of DCs. The expres-
sion of this molecule was described as a characteristic of 
fully mature DCs [29–31], and it is considered to be an 
additional marker for DC quality control [31, 32]. More-
over, the link between the amount of IL-2, INF-γ and T 
Fig. 4 IL‑4 reduces CCR7 mRNA synthesis, intracellular and surface protein content in TNF‑α‑matured DC. a RT‑PCR analysis of CCR7 and β‑actin 
mRNA expression in 5 × 104 iDC, IL‑4− and IL‑4+‑DC. b Quantification of RT‑PCR analysis in (a). Data are expressed as the ratio of expression of CCR7 
to β‑actin. The results are representative of four independent experiments. c Interleukin‑4− and IL‑4+‑DC were fixed, permeabilized and stained with 
rat PE‑anti‑CCR7 antibody (bold lines) or its isotype control (thin lines) and analyzed by flow cytometry. The results are representative of six inde‑
pendent experiments. d Mean fluorescence intensity (MFI) of CCR7 intracellular content expressed as the ratio of fluorescence intensity of specific 
labeling to background staining. The results are the mean ± SEM of the MFI from six independent experiments. e Immature DC were cultured for 
0, 8, 24 or 48 h with IL‑4 (25 ng/mL) during maturation with GM‑CSF and TNF‑α. f Immature DC were cultured for 48 h, either in the absence of (0) 
or with increasing concentrations (0.5, 1, 5, 25 ng/mL) of IL‑4 or IL‑13, during maturation with GM‑CSF and TNF‑α. g Immature DC were activated 
with GM‑CSF and TNF‑α (20 ng/mL), LPS (50 ng/mL) or sCD40L (250 ng/mL) in the absence or presence of 25 ng IL‑4. e–g Cells were stained 
with PE‑anti‑CCR7 antibody and analyzed by flow cytometry. The results are the mean ± SEM of the MFI from four to five separate experiments. 
*P < 0.05, compared to DC activated in the absence of IL‑4
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cell proliferation has been demonstrated in human DCs 
[32]. Finally, IL-4 seems able to antagonize TNF-α-DC 
maturation by down-regulation of all maturation mark-
ers, with a particularly dramatic effect being shown on 
the CD25 marker.
The secretion of IL-12p70 by DC critically regulates 
the balance between Th1 and Th2 responses and potently 
induces IFN-γ-secreting Th1 cells [33]. Our results 
revealed that TNF-α-matured DCs can secrete IL-12p70 
in response to sCD40L stimulation (a setting mimick-
ing a T-cell encounter), which demonstrates that the DC 
were not exhausted with respect to cytokine production, 
as was suggested for LPS-matured DCs [34]. Interleu-
kin-4 treatment strongly impaired IL-12p70 secretion 
and enhanced IL-10 secretion by DC, an effect consist-
ent with the reduced percentage of IFN-γ-positive CD4+ 
T cells and the lower production of IFN-γ on MLR assay. 
Since the Th2 cytokine IL-5 was weakly detected after co-
culture of CD4+ T cells with either IL-4+- or IL-4−-DC, 
these results suggest that IL-4 reduces the capacity of 
TNF-α-matured DCs to induce Th1 polarization and thus 
may decrease the efficiency of the immune response. Our 
findings are in contrast to some publications reporting a 
stimulatory effect of IL-4 on the ability of DCs to produce 
IL-12p70 [16] but in accordance with others [35, 36]. This 
discrepancy in the regulation of IL-12 secretion by IL-4 
reported by many studies could be explained by differ-
ences in the origin of the DCs (bone marrow vs. mono-
cytes and murine vs. human) but is more likely to be due 
to the different maturing agents used. The effect of IL-4 
is strong enough to antagonize the allo-stimulation that 
represents a very strong Th1 condition [37].
The induction of CCR7 expression on the surface of 
DCs governs their migration from peripheral tissues to 
lymph nodes [38–40]. DCs respond to the ligands CCL21 
and CCL19, which direct them to the peripheral lym-
phatic vessels and toward the T-cell zones of the drain-
ing lymph nodes. In  vitro transwell migration assays 
revealed that IL-4 reduced the migratory capability of 
TNF-α-matured DCs in response to the two ligands. This 
effect seems to be related to a strong reduction in CCR7 
expression at both the protein and mRNA levels. Our 
findings are the first to demonstrate that IL-4 antagonizes 
the stimulatory effect of TNF-α on the expression of 
Fig. 5 IL‑4 reduces the percentage of DC that are double positive for CCR7 and CD83 or CD25 induced by TNF‑α. IL‑4− and IL‑4+‑DC were double‑
stained with PE‑anti‑CCR7 and FITC‑anti‑CD83 (a, b) or APC‑anti‑CD25 mAbs (c, d) and analyzed by flow cytometry. The results of double labeling 
for CCR7 and CD83 (b) or CCR7 and CD25 (d) are expressed as the mean ± SEM  % of IL‑4− and IL‑4+‑DC expressing the indicated markers in five 
separate experiments. *P < 0.05, compared to IL‑4−‑DC
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CCR7, consequently decreasing DC migratory potential. 
In previous studies on DC matured with TNF-α, CCR7 
cell-surface expression was poorly detected [41, 42], 
as compared to its detection level in studies involving 
other maturing agents such as LPS, the maturation cock-
tail (TNF-α, IL-1β, IL-6 and PGE2), or sCD40L [43–45]. 
Recently, various reports have indicated that in addition 
to its role in chemotaxis, CCR7 controls the cyto-archi-
tecture, rate of endocytosis, survival, migratory speed 
and maturation of DCs [39, 46]. By inhibiting CCR7 
expression, Interleukin-4 may thus modulate all these dif-
ferent functions in DCs.
Another interesting observation is that the inhibitory 
effect of IL-4 on CCR7 expression seems to be associ-
ated with the use of TNF-α as a maturing agent because 
IL-4 had little or no effect on LPS or CD40L -matured 
DCs, respectively. This suggests that IL-4 may inter-
fere more specifically with the TNF-α signaling pathway 
[13]. Moreover, in TNF-α-matured DC, IL-4 treatment 
decreased the population of CD83+/CCR7+ cells and 
enhanced that of CD83+/CCR7− cells, which suggests 
that IL-4 dissociates the regulation of CCR7 and some 
phenotypic markers. This hypothesis was confirmed by 
cells in which IL-4 had little effect on the expression of 
co-stimulatory molecules, whilst still showing its effect 
on CCR7 expression. Our results thus reinforce previous 
observations suggesting that CCR7 expression may be 
regulated independently of other maturation-associated 
molecules [47]. Interestingly, we obtained similar results 
for the regulation of CD25 expression by IL-4, showing 
an increased population of CD83+/CD25− and CCR7−/
CD25− cells, which suggests a possible associated regula-
tion of CCR7 and CD25 by IL-4.
The mechanism(s) by which IL-4 interferes with TNF-
α-induced CCR7 expression is not known. It might be 
related to the effect of IL-4 on PGE2 synthesis, which is 
mediated by the down-regulation of enzymes such as 
phospholipase A2 (PLA2) or cycloxygenase-2 [48]. Pros-
taglandin E2 has been shown to increase CCR7 expres-
sion in DC stimulated with pro-inflammatory cytokines 
or sCD40L [44]. In our study, replacing IL-4 with IL-13, 
which enhances PLA2 expression, at least in macrophages 
[49], and PGE2 in DCs [19], had the same dose-dependent 
inhibitory effect as IL-4 on CCR7 cell-surface expression, 
suggesting that the decrease in endogenous PGE2 synthe-
sis was not involved in this process. Previous works inves-
tigating chemokine receptor expression on helper T cells 
indicated the STAT4 dependence of CCR7 expression 
in mouse Th1 cells [50]. STAT dependence of the CCR7 
expression might also be involved in human DCs, con-
necting both TNF-α and IL4R transduction signals.
Conclusion
In this study we demonstrated that TNF-α, which 
could represent a good maturation model in allogeneic 
response field, appeared as dramatically counter-produc-
tive in the induction of mature DCs for cancer therapy. 
One could speculate that removing only IL-4 from the 
maturation step will lead to more efficient DCs as they 
will express a higher mature phenotype, a better T cell 
stimulating properties and expressing CCR7 allowing 
their migration.
Finally, our study reinforces the view that the quality of 
the DC maturation stimulus, which regulates DC migra-
tion and cytokine production, may be a decisive feature 
of the immunogenicity of DCs. Further studies should try 
to locate the precise regulatory step at which IL-4 seems 
to interfere with the TNF-α signaling pathway in human 
DCs.
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